Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, NY, MARCH 13, 2026 (GLOBE NEWSWIRE) -- NEW YORK PLASTIC SURGICAL GROUP (NYPS GROUP) AND DEEP BLUE MED SPA (DBMS) ARE PROUD TO ANNOUNCE THAT THEY HAVE ONCE AGAIN BEEN RECOGNIZED BY ALLERGAN AESTHETICS AS THE #1 PROVIDER IN NEW YORK STATE, MARKING THE SECOND CONSECUTIVE YEAR EARNING THIS DISTINCTION. IN ADDITION, THE PRACTICES HAVE BEEN RANKED TOP 50 IN THE NATION FOR 2026, PLACING THEM AMONG AN ELITE GROUP OF AESTHETIC PROVIDERS ACROSS THE UNITED STATES.

NEW YORK PLASTIC SURGICAL GROUP AND DEEP BLUE MED SPA NAMED #1 IN NEW YORK BY ALLERGAN AESTHETICS FOR THE SECOND YEAR IN A ROW

ABBV-295 TREATMENT SHOWED CLINICALLY MEANINGFUL BODY WEIGHT REDUCTION FROM -7.75% TO -9.79% (LEAST-SQUARES MEAN) AT WEEK 12 (WEEKLY DOSING), TO -7.86% TO -9.73% AT WEEK 13 (EVERY OTHER WEEK AND MONTHLY DOSING AFTER WEEK 5)1 ABBV-295 DEMONSTRATED A FAVORABLE TOLERABILITY PROFILE AT ALL EVALUATED DOSE LEVELS.NO SERIOUS ADVERSE EVENTS WERE REPORTED1 DATA SUPPORT CONTINUED DEVELOPMENT OF ABBV-295 AS A POTENTIALLY DIFFERENTIATED TREATMENT FOR CHRONIC WEIGHT MANAGEMENT, WITH ANON-INCRETIN-BASED MECHANISM OF ACTION NORTH CHICAGO, ILL.

ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF ABBV-295, A LONG-ACTING AMYLIN ANALOG, IN ADULTS

NORTH CHICAGO, ILL., MARCH 3, 2026 /PRNEWSWIRE/ --ABBVIE(NYSE: ABBV) WILL PARTICIPATE IN THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, MARCH 10, 2026.

ABBVIE TO PRESENT AT THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE

IN THE PHASE 3 AFFIRM STUDY IN ADULTS WITH MODERATELY TO SEVERELY ACTIVECROHN'S DISEASE, RISANKIZUMAB (SKYRIZI) ACHIEVED SUPERIORITY FOR THE CO-PRIMARY AND RANKED SECONDARY ENDPOINTS AT WEEK 12 FOR INDUCTION DELIVERED BY SUBCUTANEOUS (SC) INJECTION VERSUS PLACEBO1 THESE DATA SUPPORT STRONG EFFICACY OFRISANKIZUMAB IN CROHN'S DISEASE WHILE PROVIDING POTENTIAL FOR AN INDUCTION CHOICE FOR PATIENTS1 THE SAFETY PROFILE OFRISANKIZUMAB SC INDUCTION WAS CONSISTENT WITH ITS KNOWN PROFILE IN CROHN'S DISEASE, WITH NO NEW SAFETY RISKS OBSERVED1 NORTH CHICAGO, ILL., MARCH 2, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND AFFIRM STUDY EVALUATING THE EFFICACY AND SAFETY OF RISANKIZUMAB (SKYRIZI) SUBCUTANEOUS (SC) INDUCTION TREATMENT VERSUS PLACEBO IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD).1 THE AFFIRM STUDY RESULTS SHOW SIGNIFICANTLY GREATER PROPORTIONS OF PATIENTS TREATED WITH RISANKIZUMAB SC INDUCTION ACHIEVED THE CO-PRIMARY ENDPOINTS OF CROHN'S DISEASE ACTIVITY INDEX (CDAI)CLINICAL REMISSIONA (55% VS.

ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 AFFIRM STUDY EVALUATING SKYRIZI (RISANKIZUMAB) SUBCUTANEOUS INDUCTION IN PATIENTS WITH CROHN'S DISEASE

NORTH CHICAGO, ILL., FEB. 24, 2026 /PRNEWSWIRE/ --ABBVIE(NYSE: ABBV) WILL PARTICIPATE IN THE TDCOWEN 46TH ANNUALHEALTH CARE CONFERENCEONTUESDAY, MARCH 3, 2026.

ABBVIE TO PRESENT AT THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE

INVESTMENT MARKS CONTINUED PROGRESS AGAINST ABBVIE'S $100 BILLION COMMITMENT TO U.S. RESEARCH AND DEVELOPMENT (R&D) AND CAPITAL INVESTMENTS, INCLUDING MANUFACTURING, OVER THE NEXT DECADE TWO NEW FACILITIES WILL BE BUILT TO ADD ADVANCED MANUFACTURING CAPABILITIES TO SUPPORT THE PRODUCTION OF NEXT-GENERATION NEUROSCIENCE AND OBESITY MEDICINES CONSTRUCTION WILL BEGIN IN SPRING 2026, WITH THE SITE FULLY OPERATIONAL IN 2029 NORTH CHICAGO, ILL., FEB. 23, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED A NEW $380 MILLION INVESTMENT TO BUILD TWO NEW ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING FACILITIES AT ITS CURRENT NORTH CHICAGO, ILLINOIS, CAMPUS.

ABBVIE TO INVEST $380 MILLION IN NORTH CHICAGO TO FURTHER EXPAND ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING IN THE UNITED STATES

FIRST ALL-ORAL, FIXED-DURATION COMBINATION REGIMEN APPROVED FOR PREVIOUSLY UNTREATED PATIENTS WITHCLL APPROVAL SUPPORTED BY DATA FROM THE PHASE 3 AMPLIFY TRIAL REGIMEN OFFERS ANOTHER OPTION FOR THE POTENTIAL OF TIME OFF TREATMENT, MARKING A MEANINGFUL ADVANCE IN LONG-TERM DISEASE MANAGEMENT NORTH CHICAGO, ILL., FEB. 20, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR THE COMBINATION REGIMEN OF VENCLEXTA (VENETOCLAX) AND ACALABRUTINIB FOR THE TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).

U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES COMBINATION TREATMENT OF VENCLEXTA (VENETOCLAX) AND ACALABRUTINIB FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

NORTH CHICAGO, ILL., FEB. 19, 2026 /PRNEWSWIRE/ --THE BOARD OF DIRECTORS OF ABBVIE INC. (NYSE: ABBV) TODAY DECLARED A QUARTERLY CASH DIVIDEND OF $1.73 PER SHARE.

ABBVIE DECLARES QUARTERLY DIVIDEND

REPORTS FULL-YEAR DILUTED EPS OF $2.36 ON A GAAP BASIS, A DECREASE OF 1.3 PERCENT; ADJUSTED DILUTED EPS OF $10.00, A DECREASE OF 1.2 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $2.76 PER SHARE RELATED TO 2025 ACQUIRED IPR&D AND MILESTONES EXPENSE  DELIVERS FULL-YEAR NET REVENUES OF $61.160 BILLION, AN INCREASE OF 8.6 PERCENT ON A REPORTED BASIS AND 8.5 PERCENT ON AN OPERATIONAL BASIS  FULL-YEAR GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $30.406 BILLION, AN INCREASE OF 14.0 PERCENT ON A REPORTED BASIS, OR 13.9 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $17.562 BILLION; GLOBAL RINVOQ NET REVENUES WERE $8.304 BILLION; GLOBAL HUMIRA NET REVENUES WERE $4.540 BILLION  FULL-YEAR GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $10.767 BILLION, AN INCREASE OF 19.6 PERCENT ON A REPORTED BASIS, OR 19.4 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $3.621 BILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $3.769 BILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $2.307 BILLION  FULL-YEAR GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $6.655 BILLION, AN INCREASE OF 1.5 PERCENT ON A REPORTED BASIS, OR 1.4 PERCENT ON AN OPERATIONAL BASIS; GLOBAL IMBRUVICA NET REVENUES WERE $2.869 BILLION; GLOBAL VENCLEXTA NET REVENUES WERE $2.792 BILLION; GLOBAL ELAHERE NET REVENUES WERE $690 MILLION  FULL-YEAR GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $4.860 BILLION, A DECREASE OF 6.1 PERCENT ON A REPORTED BASIS, OR 5.9 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $2.602 BILLION; GLOBAL JUVEDERM NET REVENUES WERE $993 MILLION  REPORTS FOURTH-QUARTER DILUTED EPS OF $1.02 ON A GAAP BASIS; ADJUSTED DILUTED EPS OF $2.71; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.71 PER SHARE RELATED TO FOURTH-QUARTER 2025 ACQUIRED IPR&D AND MILESTONES EXPENSE  DELIVERS FOURTH-QUARTER NET REVENUES OF $16.618 BILLION, AN INCREASE OF 10.0 PERCENT ON A REPORTED BASIS AND 9.5 PERC

ABBVIE REPORTS FULL-YEAR AND FOURTH-QUARTER 2025 FINANCIAL RESULTS

THE NATIONWIDE PROGRAM INVITES ELIGIBLE NATRELLE BREAST AUGMENTATION AND RECONSTRUCTION PATIENTS TO SHARE THEIR PERSONAL EXPERIENCES. NATRELLE CHAMPIONS WOMEN'S VOICES TO PROVIDE SUPPORT AT EVERY STEP OF THEIR BREAST AESTHETICS JOURNEY.

ALLERGAN AESTHETICS CONTINUES ITS MISSION OF EMPOWERING WOMEN THROUGH THE FACES OF NATRELLE TESTIMONIAL PROGRAM

SUBMISSIONS ARE SUPPORTED BY DATA FROM THE PHASE 3VITI-UP CLINICAL STUDIES DEMONSTRATING UPADACITINIB ACHIEVED THE CO-PRIMARY ENDPOINTS OF AT LEAST A 50% IMPROVEMENT IN TOTAL BODY RE-PIGMENTATION (T-VASI 50) AND AT LEAST A 75% IMPROVEMENT IN FACIAL RE-PIGMENTATION (F-VASI 75) FROM BASELINE AT WEEK 48.1 IF APPROVED,UPADACITINIB WILL BE THE FIRST SYSTEMIC MEDICATION AVAILABLE FOR PATIENTS WITH VITILIGO, ADDRESSING IMPORTANT TREATMENT NEEDS FOR THOSE LIVING WITH THE CHRONIC, UNPREDICTABLE AUTOIMMUNE DISEASE. NORTH CHICAGO, ILL.

ABBVIE SUBMITS REGULATORY APPLICATIONS TO FDA AND EMA FOR UPADACITINIB (RINVOQ) IN ADULTS AND ADOLESCENTS WITH VITILIGO

~3 OUT OF 4 RESPONDENTS SAID MIGRAINE ATTACKS HAVE STOOD IN THE WAY OF ROMANTIC RELATIONSHIPS, ACCORDING TO NEW HARRIS POLL SURVEY WIFE, MOTHER, COUNTRY MUSIC STAR, AND ENTREPRENEUR JESSIE JAMES DECKER SHARES HER PERSONAL EXPERIENCE LIVING WITH MIGRAINE LOVE IN MIND ENCOURAGES CANDID CONVERSATIONS ABOUT MIGRAINE WITH HEALTHCARE PROVIDERS TO DEVELOP A PERSONALIZED CARE PLAN NORTH CHICAGO, ILL., JAN. 29, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) ANNOUNCED TODAY THE LAUNCH OF LOVE IN MIND, AN EDUCATIONAL INITIATIVE THAT SEEKS TO ELEVATE THE CONVERSATION ABOUT THE EMOTIONAL IMPACT OF LIVING WITH MIGRAINE, BEYOND THE PHYSICAL SYMPTOMS, WITH A FOCUS ON DATING AND ROMANTIC RELATIONSHIPS.

ABBVIE LAUNCHES LOVE IN MIND TO SPOTLIGHT THE EMOTIONAL IMPACT OF MIGRAINE ON ROMANTIC RELATIONSHIPS

- N INE E-POSTERS PRESENTING COMPREHENSIVE ALLERGAN AESTHETICS PORTFOLIO DATA SPANNING FIRST-IN-CLASS BOTULINUM NEUROTOXIN SEROTYPE E (TRENIBOTULINUMTOXINE, "TRENIBOTE"), ONABOTULINUMTOXINA, HYALURONIC ACID-BASED FILLERS AND AN INNOVATIVE FILLER WITH BIOSTIMULATORY PROPERTIES - POOLED PHASE 3 EFFICACY, SAFETY AND PATIENT SATISFACTION DATA FOR TRENIBOTULINUMTOXINE, A FIRST-IN-CLASS BOTULINUM NEUROTOXIN SEROTYPE E THAT DELIVERS RAPID RESULTS WITH A SHORT-DURATION OF EFFECT - RESULTS FROM TWO PHASE 4 STUDIES OF ONABOTULINUMTOXINA FOR UPPER FACIAL LINES POINT TO THE BENEFIT OF LONG-TERM USE AND PATIENT SATISFACTION WITH ACHIEVING NATURAL OUTCOMES. IRVINE, CALIF.

ALLERGAN AESTHETICS UNVEILS NEW DATA ACROSS FACIAL INJECTABLES ON-MARKET AND EMERGING PORTFOLIO AT IMCAS 2026 SHOWCASING ENDURING STRENGTH IN ADVANCING AESTHETICS MEDICINE

CHICAGO--(BUSINESS WIRE)--THE ABBVIE FOUNDATION, A 501(C)(3) NONPROFIT WORKING TO DRIVE TRANSFORMATIVE CHANGE AND ADVANCE HEALTH EQUITY IN COMMUNITIES WORLDWIDE, IN PARTNERSHIP WITH MATTER, THE PREMIER HEALTH CARE INCUBATOR AND INNOVATION HUB, ANNOUNCED TODAY A CALL FOR APPLICATIONS FOR THE 2026 ABBVIE FOUNDATION HEALTH EQUITY ACCELERATOR. NOW IN ITS SECOND YEAR, THE ACCELERATOR PROVIDES RESOURCES AND COACHING TO SELECT NONPROFIT ORGANIZATIONS TO ADVANCE THEIR INNOVATIVE SOLUTIONS THAT EXPAND A.

THE ABBVIE FOUNDATION IS NOW ACCEPTING APPLICATIONS TO PARTICIPATE IN THE 2026 ABBVIE FOUNDATION HEALTH EQUITY ACCELERATOR

BASED ON THE TOPLINE RESULTS FROM THE EPCORE DLBCL-1 TRIAL, ABBVIE ALONG WITH PARTNER GENMAB WILL ENGAGE GLOBAL REGULATORY AUTHORITIES TO DISCUSS NEXT STEPS NORTH CHICAGO, ILL., JAN. 16, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED TOPLINE RESULTS FROM THE PHASE 3 EPCORE DLBCL-1 TRIAL EVALUATING EPCORITAMAB, A T-CELL ENGAGING BISPECIFIC ANTIBODY ADMINISTERED SUBCUTANEOUSLY, COMPARED TO INVESTIGATOR'S CHOICE OF CHEMOIMMUNOTHERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).

ABBVIE ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY CD3XCD20) FROM PHASE 3 EPCORE DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

AbbVie Inc.

ABBV

Price

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABBV